Global and China Drugs for Renal Cell Carcinoma Research Report to 2021
The global Drugs for Treatment of Renal Cell Carcinoma market was valued at USD 26.4 Billion in 2015, and is projected to reach USD 35 Billion by 2021, at a CAGR of 5.81% between 2016 and 2021. Aging population leads to increase the prevalence of Renal Cell Carcinoma, polypharmacy rates rise, the expected drugs enter the market which is studying, and the market quickly absorb those drugs.
This report studies Drugs for Treatment of Renal Cell Carcinoma in Global and China market, focuses on price, sales, market share and revenue of each type in global China. This report also focuses on the sales (consumption), production and market share of Drugs for Treatment of Renal Cell Carcinoma in India and China, forecast to 2020, from 2015.
Split by product types, with sales, revenue, market share and price of each type, as well as the types and each type price of key manufacturers, through interviewing nationwide hospital, in 2015 and 2016, covering
Nexavar
Votrient
Inlyta
Sutent
Temsirolimus
Everolimus Tablets
Split by manufacturers, this report focuses on the sales, price of each type, average price of Treatment of Renal Cell Carcinoma, revenue and market share, for each manufacturer in 2015 and 2016. Top players, covering
Bayer
Roche
Novartis Pharma
Wyeth
Pfizer
GlaxoSmithKline
SP ACCURE Labs
Natco
Split by regions, this report focuses on the sales (consumption), market share, growth rate by manufacturer of Drugs for Treatment of Age-related Macular Degeneration in Europe and China, from 2011 to 2020 (forecast), covering
Europe
China
With 118 pages, 138 charts and eight chapters, to display the market present situation and future, clearly and deeply.
This report studies Drugs for Treatment of Renal Cell Carcinoma in Global and China market, focuses on price, sales, market share and revenue of each type in global China. This report also focuses on the sales (consumption), production and market share of Drugs for Treatment of Renal Cell Carcinoma in India and China, forecast to 2020, from 2015.
Split by product types, with sales, revenue, market share and price of each type, as well as the types and each type price of key manufacturers, through interviewing nationwide hospital, in 2015 and 2016, covering
Nexavar
Votrient
Inlyta
Sutent
Temsirolimus
Everolimus Tablets
Split by manufacturers, this report focuses on the sales, price of each type, average price of Treatment of Renal Cell Carcinoma, revenue and market share, for each manufacturer in 2015 and 2016. Top players, covering
Bayer
Roche
Novartis Pharma
Wyeth
Pfizer
GlaxoSmithKline
SP ACCURE Labs
Natco
Split by regions, this report focuses on the sales (consumption), market share, growth rate by manufacturer of Drugs for Treatment of Age-related Macular Degeneration in Europe and China, from 2011 to 2020 (forecast), covering
Europe
China
With 118 pages, 138 charts and eight chapters, to display the market present situation and future, clearly and deeply.
1 DRUGS FOR TREATMENT OF RENAL CELL CARCINOMA OVERVIEW AND EACH TYPE
1.1 Product Overview of Drugs for Treatment of Renal Cell Carcinoma
1.1.1 Definition and Product Scope of Drugs for Treatment of Renal Cell Carcinoma
1.1.2 Global Market Size (Value and Volume) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
1.1.3 China Market Size (Value and Volume) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
1.2 Product Segments and Price of Each Type
1.2.1 Product Type of Key Manufacturers
1.2.2 Price List of Each Type in 2015 to 2016
1.2.3 Market Share and Growth Rate of Each Type
1.2.4 Nexavar Specification and Price in 2015 and 2016
1.2.5 Votrient Specification and Price in 2015 and 2016
1.2.6 Inlyta Specification and Price in 2015 and 2016
1.2.7 Sutent Specification and Price in 2015 and 2016
1.2.8 Temsirolimus Specification and Price in 2015 and 2016
1.2.9 Everolimus Tablets Specification and Price in 2015 and 2016
1.3 Price List (Interviewed) of Each Type for Key Manufacturers in 2015 and 2016
1.3.1 Price List (Interviewed) of Nexavar by Key Manufacturers
1.3.2 Price List (Interviewed) of Votrient by Key Manufacturers
1.3.3 Price List (Interviewed) of Inlyta by Key Manufacturers
1.3.4 Price List (Interviewed) of Sutent by Key Manufacturers
1.3.5 Price List (Interviewed) of Temsirolimus by Key Manufacturers
1.3.6 Price List (Interviewed) of Everolimus Tablets by Key Manufacturers
2 COMPETITION ANALYSIS BY MANUFACTURERS IN GLOBAL AND CHINA
2.1 Global Market Drugs for Treatment of Renal Cell Carcinoma Sales and Share List of Key Manufacturers 2010 to 2015
2.2 Global Market Drugs for Treatment of Renal Cell Carcinoma Revenue and Share List of Key Manufacturers 2010 to 2015
2.3 Global Drugs for Treatment of Renal Cell Carcinoma Average Price List of Key Manufacturers 2010 to 2015
2.4 China Market Drugs for Treatment of Renal Cell Carcinoma Sales and Share List of Key Manufacturers 2010 to 2015
2.5 China Market Drugs for Treatment of Renal Cell Carcinoma Revenue and Share List of Key Manufacturers 2010 to 2015
2.6 China Drugs for Treatment of Renal Cell Carcinoma Average Price List of Key Manufacturers 2010 to 2015
3 SALES AND REVENUE SEGMENTS OF EACH TYPE 2015 TO 2016
3.1 Global Sales and Revenue Segments of Each Type 2015 to 2016
3.1.1 Global Sales and Market Share of Each Type 2015 to 2016
3.1.2 Global Revenue and Market Share of Each Type 2015 to 2016
3.2 Nexavar Sales and Growth Rate 2015 to 2020
3.3 Votrient Sales and Growth Rate 2015 to 2020
3.4 Inlyta Sales and Growth Rate 2015 to 2020
3.5 Sutent Sales and Growth Rate 2015 to 2020
3.6 Temsirolimus Sales and Growth Rate 2015 to 2020
3.7 Everolimus Tablets Sales and Growth Rate 2015 to 2020
4 MARKET SEGMENTS AND FORECAST OF DRUGS FOR TREATMENT OF RENAL CELL CARCINOMA BY REGIONS
4.1 Sales (Consumption) and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015-2020
4.1.1 Sales and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015-2020
4.1.2 Sales Growth Rate Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
4.2 Price and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
4.2.1 Price and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
4.2.2 Price Growth Rate Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
4.3 China Market Forecast to 2020
4.3.1 China Sales and market share of Drugs for Treatment of Renal Cell Carcinoma 2015 to 2020
4.4 India Market Forecast to 2020
4.4.1 India Sales and market share of Drugs for Treatment of Renal Cell Carcinoma 2015 to 2020
5 RAW MATERIALS AND APPLICATIONS
5.1 Key Raw Materials and Price Analysis for Nexavar
5.1.1 Key Raw Materials for Nexavar
5.1.2 Price Forecast of Key Raw Materials for Nexavar 2016 to 2021
5.2 Key Raw Materials and Price Analysis for Votrient
5.2.1 Key Raw Materials for Votrient
5.2.2 Price Forecast of Key Raw Materials for Votrient 2016 to 2021
5.3 Key Raw Materials and Price Analysis for Inlyta
5.3.1 Key Raw Materials for Inlyta
5.3.2 Price Forecast of Key Raw Materials for Inlyta n 2016 to 2021
5.4 Key Raw Materials and Price Analysis for Sutent
5.4.1 Key Raw Materials for Sutent
5.4.2 Price Forecast of Key Raw Materials for Sutent 2016 to 2021
5.5 Key Raw Materials and Price Analysis for Temsirolimus
5.5.1 Key Raw Materials for Temsirolimus
5.5.2 Price Forecast of Key Raw Materials for Temsirolimus 2016 to 2021
5.6 Key Raw Materials and Price Analysis for Everolimus Tablets
5.6.1 Key Raw Materials for Everolimus Tablets
5.6.2 Price Forecast of Key Raw Materials for Everolimus Tablets 2016 to 2021
6 KEY MANUFACTURERS ANALYSIS OF DRUGS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION
6.1 Bayer
6.1.1 Company Basic Information
6.1.2 Nexavar (Specification and Price)
6.1.2.1 Nexavar 0.2g, Price, Sales Value and Market Share of Bayer
6.1.3 Sales Value, Gross Margin 2011-2016
6.1.3.1 Sales Value, Gross Margin and Growth rate of Bayer Nexavar 0.2g
6.1.4 Interviewee, Name and Contact
6.2 Natco
6.2.1 Company Basic Information
6.2.2 Nexavar (Specification and Price)
6.2.2.1 Nexavar 0.2g, Price, Sales Value and Market Share of Natco
6.2.3 Sales Value, Gross Margin 2011-2016
6.2.3.1 Sales Value, Gross Margin and Growth rate of Natco Nexavar 0.2g
6.2.4 Interviewee, Name and Contact
6.3 GlaxoSmithKline
6.3.1 Company Basic Information
6.3.2 Votrient (Specification and Price)
6.3.2.1 Votrient 200mg30T, Price, Sales Value and Market Share of GlaxoSmithKline
6.3.3 Sales Value, Gross Margin 2011-2016
6.3.3.1 Sales Value, Gross Margin and Growth rate of GlaxoSmithKline Votrient 200mg30T
6.3.4 Interviewee, Name and Contact
6.4 Pfizer
6.4.1 Company Basic Information
6.4.2 Inlyta (Specification and Price)
6.4.2.1 Inlyta 1mg28T, Price, Sales Value and Market Share of Pfizer
6.4.2.2 Inlyta 5mg28T, Price, Sales Value and Market Share of Pfizer
6.4.3 Sales Value, Gross Margin 2011-2016
6.4.3.1 Sales Value, Gross Margin and Growth rate of Pfizer Inlyta 1mg28T
6.4.3.2 Sales Value, Gross Margin and Growth rate of Pfizer Inlyta 5mg28T
6.4.4 Interviewee, Name and Contact
6.5 SP Accure Labs
6.5.1 Company Basic Information
6.5.2 Sutent (Specification and Price)
6.5.2.1 Sutent 12.5mg, Price, Sales Value and Market Share of SP Accure Labs
6.5.2.2 Sutent 25mg, Price, Sales Value and Market Share of SP Accure Labs
6.5.2.3 Sutent 50mg, Price, Sales Value and Market Share of SP Accure Labs
6.5.3 Sales Value, Gross Margin 2011-2016
6.5.3.1 Sales Value, Gross Margin and Growth rate of SP Accure Labs Sutent 12.5mg
6.5.3.2 Sales Value, Gross Margin and Growth rate of SP Accure Labs Sutent 25mg
6.5.3.1 Sales Value, Gross Margin and Growth rate of SP Accure Labs Sutent 50mg
6.5.4 Interviewee, Name and Contact
6.6 Pfizer
6.6.1 Company Basic Information
6.6.2 Sutent (Specification and Price)
6.6.2.1 Sutent 12.5mg, Price, Sales Value and Market Share of Pfizer
6.6.2.2 Sutent 25mg, Price, Sales Value and Market Share of Pfizer
6.6.2.3 Sutent 50mg, Price, Sales Value and Market Share of Pfizer
6.6.3 Sales Value, Gross Margin 2011-2016
6.6.3.1 Sales Value, Gross Margin and Growth rate of Sutent 12.5mg
6.6.3.2 Sales Value, Gross Margin and Growth rate of Sutent 25mg
6.6.3.1 Sales Value, Gross Margin and Growth rate of Sutent 50mg
6.6.4 Interviewee, Name and Contact
6.7 Wyeth
6.7.1 Company Basic Information
6.7.2 Temsirolimus (Specification and Price)
6.7.2.1 Temsirolimus 1mg10T, Price, Sales Value and Market Share of Wyeth
6.7.3 Sales Value, Gross Margin 2011-2016
6.7.3.1 Sales Value, Gross Margin and Growth rate of Wyeth Temsirolimus 1mg10T
6.7.4 Interviewee, Name and Contact
6.8 Pfizer
6.8.1 Company Basic Information
6.8.2 Temsirolimus (Specification and Price)
6.8.2.1 Temsirolimus 1mg10T, Price, Sales Value and Market Share of Pfizer
6.8.3 Sales Value, Gross Margin 2011-2016
6.8.3.1 Sales Value, Gross Margin and Growth rate of Pfizer Temsirolimus 1mg10T
6.8.4 Interviewee, Name and Contact
6.9 Novartis Pharma
6.9.1 Company Basic Information
6.9.2 Everolimus Tablets (Specification and Price)
6.9.2.1 Everolimus Tablets 2.5mg, Price, Sales Value and Market Share of Novartis Pharma
6.9.2.2 Everolimus Tablets 5mg, Price, Sales Value and Market Share of Novartis Pharma
6.9.3 Sales Value, Gross Margin 2011-2016
6.9.3.1 Sales Value, Gross Margin and Growth rate of Novartis Pharma Everolimus Tablets 2.5mg
6.9.3.2 Sales Value, Gross Margin and Growth rate of Novartis Pharma Everolimus Tablets 5mg
6.9.4 Interviewee, Name and Contact
7 TECHNOLOGY DEVELOPMENT TREND
7.1 Manufacturing Process of Drugs for Treatment of Erectile Dysfunction
7.2 Analysis of Manufacturing Process
7.3 Development Trend
8 WORLDWIDE, AN ESTIMATED TIME FOR THE DRUG IN ERECTILE DYSFUNCTION RESEARCH TO MARKET
9 PATENT EXPIRATION TIME ANALYSIS
9.1 Viagra patent expires in China and sales
9.2 Cialis patent expires in China and sales
9.3 Levitra patent expires in China and sales
10 RESEARCH FINDINGS AND CONCLUSION
1.1 Product Overview of Drugs for Treatment of Renal Cell Carcinoma
1.1.1 Definition and Product Scope of Drugs for Treatment of Renal Cell Carcinoma
1.1.2 Global Market Size (Value and Volume) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
1.1.3 China Market Size (Value and Volume) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
1.2 Product Segments and Price of Each Type
1.2.1 Product Type of Key Manufacturers
1.2.2 Price List of Each Type in 2015 to 2016
1.2.3 Market Share and Growth Rate of Each Type
1.2.4 Nexavar Specification and Price in 2015 and 2016
1.2.5 Votrient Specification and Price in 2015 and 2016
1.2.6 Inlyta Specification and Price in 2015 and 2016
1.2.7 Sutent Specification and Price in 2015 and 2016
1.2.8 Temsirolimus Specification and Price in 2015 and 2016
1.2.9 Everolimus Tablets Specification and Price in 2015 and 2016
1.3 Price List (Interviewed) of Each Type for Key Manufacturers in 2015 and 2016
1.3.1 Price List (Interviewed) of Nexavar by Key Manufacturers
1.3.2 Price List (Interviewed) of Votrient by Key Manufacturers
1.3.3 Price List (Interviewed) of Inlyta by Key Manufacturers
1.3.4 Price List (Interviewed) of Sutent by Key Manufacturers
1.3.5 Price List (Interviewed) of Temsirolimus by Key Manufacturers
1.3.6 Price List (Interviewed) of Everolimus Tablets by Key Manufacturers
2 COMPETITION ANALYSIS BY MANUFACTURERS IN GLOBAL AND CHINA
2.1 Global Market Drugs for Treatment of Renal Cell Carcinoma Sales and Share List of Key Manufacturers 2010 to 2015
2.2 Global Market Drugs for Treatment of Renal Cell Carcinoma Revenue and Share List of Key Manufacturers 2010 to 2015
2.3 Global Drugs for Treatment of Renal Cell Carcinoma Average Price List of Key Manufacturers 2010 to 2015
2.4 China Market Drugs for Treatment of Renal Cell Carcinoma Sales and Share List of Key Manufacturers 2010 to 2015
2.5 China Market Drugs for Treatment of Renal Cell Carcinoma Revenue and Share List of Key Manufacturers 2010 to 2015
2.6 China Drugs for Treatment of Renal Cell Carcinoma Average Price List of Key Manufacturers 2010 to 2015
3 SALES AND REVENUE SEGMENTS OF EACH TYPE 2015 TO 2016
3.1 Global Sales and Revenue Segments of Each Type 2015 to 2016
3.1.1 Global Sales and Market Share of Each Type 2015 to 2016
3.1.2 Global Revenue and Market Share of Each Type 2015 to 2016
3.2 Nexavar Sales and Growth Rate 2015 to 2020
3.3 Votrient Sales and Growth Rate 2015 to 2020
3.4 Inlyta Sales and Growth Rate 2015 to 2020
3.5 Sutent Sales and Growth Rate 2015 to 2020
3.6 Temsirolimus Sales and Growth Rate 2015 to 2020
3.7 Everolimus Tablets Sales and Growth Rate 2015 to 2020
4 MARKET SEGMENTS AND FORECAST OF DRUGS FOR TREATMENT OF RENAL CELL CARCINOMA BY REGIONS
4.1 Sales (Consumption) and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015-2020
4.1.1 Sales and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015-2020
4.1.2 Sales Growth Rate Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
4.2 Price and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
4.2.1 Price and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
4.2.2 Price Growth Rate Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
4.3 China Market Forecast to 2020
4.3.1 China Sales and market share of Drugs for Treatment of Renal Cell Carcinoma 2015 to 2020
4.4 India Market Forecast to 2020
4.4.1 India Sales and market share of Drugs for Treatment of Renal Cell Carcinoma 2015 to 2020
5 RAW MATERIALS AND APPLICATIONS
5.1 Key Raw Materials and Price Analysis for Nexavar
5.1.1 Key Raw Materials for Nexavar
5.1.2 Price Forecast of Key Raw Materials for Nexavar 2016 to 2021
5.2 Key Raw Materials and Price Analysis for Votrient
5.2.1 Key Raw Materials for Votrient
5.2.2 Price Forecast of Key Raw Materials for Votrient 2016 to 2021
5.3 Key Raw Materials and Price Analysis for Inlyta
5.3.1 Key Raw Materials for Inlyta
5.3.2 Price Forecast of Key Raw Materials for Inlyta n 2016 to 2021
5.4 Key Raw Materials and Price Analysis for Sutent
5.4.1 Key Raw Materials for Sutent
5.4.2 Price Forecast of Key Raw Materials for Sutent 2016 to 2021
5.5 Key Raw Materials and Price Analysis for Temsirolimus
5.5.1 Key Raw Materials for Temsirolimus
5.5.2 Price Forecast of Key Raw Materials for Temsirolimus 2016 to 2021
5.6 Key Raw Materials and Price Analysis for Everolimus Tablets
5.6.1 Key Raw Materials for Everolimus Tablets
5.6.2 Price Forecast of Key Raw Materials for Everolimus Tablets 2016 to 2021
6 KEY MANUFACTURERS ANALYSIS OF DRUGS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION
6.1 Bayer
6.1.1 Company Basic Information
6.1.2 Nexavar (Specification and Price)
6.1.2.1 Nexavar 0.2g, Price, Sales Value and Market Share of Bayer
6.1.3 Sales Value, Gross Margin 2011-2016
6.1.3.1 Sales Value, Gross Margin and Growth rate of Bayer Nexavar 0.2g
6.1.4 Interviewee, Name and Contact
6.2 Natco
6.2.1 Company Basic Information
6.2.2 Nexavar (Specification and Price)
6.2.2.1 Nexavar 0.2g, Price, Sales Value and Market Share of Natco
6.2.3 Sales Value, Gross Margin 2011-2016
6.2.3.1 Sales Value, Gross Margin and Growth rate of Natco Nexavar 0.2g
6.2.4 Interviewee, Name and Contact
6.3 GlaxoSmithKline
6.3.1 Company Basic Information
6.3.2 Votrient (Specification and Price)
6.3.2.1 Votrient 200mg30T, Price, Sales Value and Market Share of GlaxoSmithKline
6.3.3 Sales Value, Gross Margin 2011-2016
6.3.3.1 Sales Value, Gross Margin and Growth rate of GlaxoSmithKline Votrient 200mg30T
6.3.4 Interviewee, Name and Contact
6.4 Pfizer
6.4.1 Company Basic Information
6.4.2 Inlyta (Specification and Price)
6.4.2.1 Inlyta 1mg28T, Price, Sales Value and Market Share of Pfizer
6.4.2.2 Inlyta 5mg28T, Price, Sales Value and Market Share of Pfizer
6.4.3 Sales Value, Gross Margin 2011-2016
6.4.3.1 Sales Value, Gross Margin and Growth rate of Pfizer Inlyta 1mg28T
6.4.3.2 Sales Value, Gross Margin and Growth rate of Pfizer Inlyta 5mg28T
6.4.4 Interviewee, Name and Contact
6.5 SP Accure Labs
6.5.1 Company Basic Information
6.5.2 Sutent (Specification and Price)
6.5.2.1 Sutent 12.5mg, Price, Sales Value and Market Share of SP Accure Labs
6.5.2.2 Sutent 25mg, Price, Sales Value and Market Share of SP Accure Labs
6.5.2.3 Sutent 50mg, Price, Sales Value and Market Share of SP Accure Labs
6.5.3 Sales Value, Gross Margin 2011-2016
6.5.3.1 Sales Value, Gross Margin and Growth rate of SP Accure Labs Sutent 12.5mg
6.5.3.2 Sales Value, Gross Margin and Growth rate of SP Accure Labs Sutent 25mg
6.5.3.1 Sales Value, Gross Margin and Growth rate of SP Accure Labs Sutent 50mg
6.5.4 Interviewee, Name and Contact
6.6 Pfizer
6.6.1 Company Basic Information
6.6.2 Sutent (Specification and Price)
6.6.2.1 Sutent 12.5mg, Price, Sales Value and Market Share of Pfizer
6.6.2.2 Sutent 25mg, Price, Sales Value and Market Share of Pfizer
6.6.2.3 Sutent 50mg, Price, Sales Value and Market Share of Pfizer
6.6.3 Sales Value, Gross Margin 2011-2016
6.6.3.1 Sales Value, Gross Margin and Growth rate of Sutent 12.5mg
6.6.3.2 Sales Value, Gross Margin and Growth rate of Sutent 25mg
6.6.3.1 Sales Value, Gross Margin and Growth rate of Sutent 50mg
6.6.4 Interviewee, Name and Contact
6.7 Wyeth
6.7.1 Company Basic Information
6.7.2 Temsirolimus (Specification and Price)
6.7.2.1 Temsirolimus 1mg10T, Price, Sales Value and Market Share of Wyeth
6.7.3 Sales Value, Gross Margin 2011-2016
6.7.3.1 Sales Value, Gross Margin and Growth rate of Wyeth Temsirolimus 1mg10T
6.7.4 Interviewee, Name and Contact
6.8 Pfizer
6.8.1 Company Basic Information
6.8.2 Temsirolimus (Specification and Price)
6.8.2.1 Temsirolimus 1mg10T, Price, Sales Value and Market Share of Pfizer
6.8.3 Sales Value, Gross Margin 2011-2016
6.8.3.1 Sales Value, Gross Margin and Growth rate of Pfizer Temsirolimus 1mg10T
6.8.4 Interviewee, Name and Contact
6.9 Novartis Pharma
6.9.1 Company Basic Information
6.9.2 Everolimus Tablets (Specification and Price)
6.9.2.1 Everolimus Tablets 2.5mg, Price, Sales Value and Market Share of Novartis Pharma
6.9.2.2 Everolimus Tablets 5mg, Price, Sales Value and Market Share of Novartis Pharma
6.9.3 Sales Value, Gross Margin 2011-2016
6.9.3.1 Sales Value, Gross Margin and Growth rate of Novartis Pharma Everolimus Tablets 2.5mg
6.9.3.2 Sales Value, Gross Margin and Growth rate of Novartis Pharma Everolimus Tablets 5mg
6.9.4 Interviewee, Name and Contact
7 TECHNOLOGY DEVELOPMENT TREND
7.1 Manufacturing Process of Drugs for Treatment of Erectile Dysfunction
7.2 Analysis of Manufacturing Process
7.3 Development Trend
8 WORLDWIDE, AN ESTIMATED TIME FOR THE DRUG IN ERECTILE DYSFUNCTION RESEARCH TO MARKET
9 PATENT EXPIRATION TIME ANALYSIS
9.1 Viagra patent expires in China and sales
9.2 Cialis patent expires in China and sales
9.3 Levitra patent expires in China and sales
10 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES AND FIGURES
Figure Picture of Drugs for Treatment of Renal Cell Carcinoma
Figure Global Market Size (Value) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
Figure Global Market Size (Volume) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
Figure China Market Size (Value) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
Figure China Market Size (Volume) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
Table Product Type of Key Manufacturers
Table Price List of Each Type
Table Market Share of Each Type
Figure Growth Rate of Each Type 2015 to 2016
Figure Picture of Nexavar
Table Specification and Price of Nexavar in 2015 and 2016
Figure Picture of Votrient
Table Specification and Price of Votrient in 2015 and 2016
Figure Picture of Inlyta
Table Specification and Price of Inlyta in 2015 and 2016
Figure Picture of Sutent
Table Specification and Price of Sutent in 2015 and 2016
Figure Picture of Temsirolimus
Table Specification and Price of Temsirolimus in 2015 and 2016
Figure Picture of Everolimus Tablets
Table Specification and Price of Everolimus Tablets in 2015 and 2016
Table Price List (Interviewed) of Nexavar by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Votrient by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Inlyta by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Sutent Tablets by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Temsirolimus Tablets by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Everolimus Tablets by Key Manufacturers in 2015 and 2016
Table Global Market Drugs for Treatment of Renal Cell Carcinoma Sales List of Key Manufacturers 2010 to 2015
Table Global Market Drugs for Treatment of Renal Cell Carcinoma Sales Share List of Key Manufacturers 2010 to 2015
Table Global Market Drugs for Treatment of Renal Cell Carcinoma Revenue List of Key Manufacturers 2010 to 2015
Table Global Market Drugs for Treatment of Renal Cell Carcinoma Revenue Share List of Key Manufacturers 2010 to 2015
Table Global Drugs for Treatment of Renal Cell Carcinoma Average Price List of Key Manufacturers 2010 to 2015
Table China Market Drugs for Treatment of Renal Cell Carcinoma Sales List of Key Manufacturers 2010 to 2015
Table China Market Drugs for Treatment of Renal Cell Carcinoma Sales Share List of Key Manufacturers 2010 to 2015
Table China Market Drugs for Treatment of Renal Cell Carcinoma Revenue List of Key Manufacturers 2010 to 2015
Table China Market Drugs for Treatment of Renal Cell Carcinoma Revenue Share List of Key Manufacturers 2010 to 2015
Table China Drugs for Treatment of Renal Cell Carcinoma Average Price List of Key Manufacturers 2010 to 2015
Table Global Sales of Each Type 2015 to 2016
Table Global Sales Market Share of Each Type 2015 to 2016
Table Global Revenue of Each Type 2015 to 2016
Table Global Revenue Market Share of Each Type 2015 to 2016
Figure Nexavar Sales and Growth Rate 2015 to 2020
Figure Votrient Sales and Growth Rate 2015 to 2020
Figure Inlyta Sales and Growth Rate 2015 to 2020
Figure Sutent Sales and Growth Rate 2015 to 2020
Figure Temsirolimus Sales and Growth Rate 2015 to 2020
Figure Everolimus Tablets Sales and Growth Rate 2015 to 2020
Table Sales and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015-2020
Figure Sales Growth Rate Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
Table Price and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
Figure Price Growth Rate Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
Table China Sales and market share of Drugs for Treatment of Renal Cell Carcinoma 2015 to 2020
Table India Sales and market share of Drugs for Treatment of Renal Cell Carcinoma 2015 to 2020
Table Key Raw Materials for Nexavar
Table Price Forecast of Key Raw Materials for Nexavar
Table Key Raw Materials for Votrient
Table Price Forecast of Key Raw Materials for Votrient
Table Key Raw Materials for Inlyta
Table Price Forecast of Key Raw Materials for Inlyta
Table Key Raw Materials for Sutent
Table Price Forecast of Key Raw Materials for Sutent
Table Key Raw Materials for Temsirolimus
Table Price Forecast of Key Raw Materials for Temsirolimus
Table Key Raw Materials for Everolimus Tablets
Table Price Forecast of Key Raw Materials for Everolimus Tablets
Table Bayer Basic Information List
Table Natco Basic Information List
Table GlaxoSmithKline Basic Information List
Table Pfizer Basic Information List
Table SP Accure Labs by Share Ltd Basic Information List
TablePfizer Basic Information List
Table Wyeth Basic Information List
Table Pfizer Basic Information List
Table Novartis Pharma Basic Information List
Figure Picture of Drugs for Treatment of Renal Cell Carcinoma
Figure Global Market Size (Value) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
Figure Global Market Size (Volume) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
Figure China Market Size (Value) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
Figure China Market Size (Volume) of Drugs for Treatment of Renal Cell Carcinoma 2015-2020
Table Product Type of Key Manufacturers
Table Price List of Each Type
Table Market Share of Each Type
Figure Growth Rate of Each Type 2015 to 2016
Figure Picture of Nexavar
Table Specification and Price of Nexavar in 2015 and 2016
Figure Picture of Votrient
Table Specification and Price of Votrient in 2015 and 2016
Figure Picture of Inlyta
Table Specification and Price of Inlyta in 2015 and 2016
Figure Picture of Sutent
Table Specification and Price of Sutent in 2015 and 2016
Figure Picture of Temsirolimus
Table Specification and Price of Temsirolimus in 2015 and 2016
Figure Picture of Everolimus Tablets
Table Specification and Price of Everolimus Tablets in 2015 and 2016
Table Price List (Interviewed) of Nexavar by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Votrient by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Inlyta by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Sutent Tablets by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Temsirolimus Tablets by Key Manufacturers in 2015 and 2016
Table Price List (Interviewed) of Everolimus Tablets by Key Manufacturers in 2015 and 2016
Table Global Market Drugs for Treatment of Renal Cell Carcinoma Sales List of Key Manufacturers 2010 to 2015
Table Global Market Drugs for Treatment of Renal Cell Carcinoma Sales Share List of Key Manufacturers 2010 to 2015
Table Global Market Drugs for Treatment of Renal Cell Carcinoma Revenue List of Key Manufacturers 2010 to 2015
Table Global Market Drugs for Treatment of Renal Cell Carcinoma Revenue Share List of Key Manufacturers 2010 to 2015
Table Global Drugs for Treatment of Renal Cell Carcinoma Average Price List of Key Manufacturers 2010 to 2015
Table China Market Drugs for Treatment of Renal Cell Carcinoma Sales List of Key Manufacturers 2010 to 2015
Table China Market Drugs for Treatment of Renal Cell Carcinoma Sales Share List of Key Manufacturers 2010 to 2015
Table China Market Drugs for Treatment of Renal Cell Carcinoma Revenue List of Key Manufacturers 2010 to 2015
Table China Market Drugs for Treatment of Renal Cell Carcinoma Revenue Share List of Key Manufacturers 2010 to 2015
Table China Drugs for Treatment of Renal Cell Carcinoma Average Price List of Key Manufacturers 2010 to 2015
Table Global Sales of Each Type 2015 to 2016
Table Global Sales Market Share of Each Type 2015 to 2016
Table Global Revenue of Each Type 2015 to 2016
Table Global Revenue Market Share of Each Type 2015 to 2016
Figure Nexavar Sales and Growth Rate 2015 to 2020
Figure Votrient Sales and Growth Rate 2015 to 2020
Figure Inlyta Sales and Growth Rate 2015 to 2020
Figure Sutent Sales and Growth Rate 2015 to 2020
Figure Temsirolimus Sales and Growth Rate 2015 to 2020
Figure Everolimus Tablets Sales and Growth Rate 2015 to 2020
Table Sales and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015-2020
Figure Sales Growth Rate Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
Table Price and Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
Figure Price Growth Rate Forecast of Drugs for Treatment of Renal Cell Carcinoma by Regions 2015 to 2020
Table China Sales and market share of Drugs for Treatment of Renal Cell Carcinoma 2015 to 2020
Table India Sales and market share of Drugs for Treatment of Renal Cell Carcinoma 2015 to 2020
Table Key Raw Materials for Nexavar
Table Price Forecast of Key Raw Materials for Nexavar
Table Key Raw Materials for Votrient
Table Price Forecast of Key Raw Materials for Votrient
Table Key Raw Materials for Inlyta
Table Price Forecast of Key Raw Materials for Inlyta
Table Key Raw Materials for Sutent
Table Price Forecast of Key Raw Materials for Sutent
Table Key Raw Materials for Temsirolimus
Table Price Forecast of Key Raw Materials for Temsirolimus
Table Key Raw Materials for Everolimus Tablets
Table Price Forecast of Key Raw Materials for Everolimus Tablets
Table Bayer Basic Information List
Table Natco Basic Information List
Table GlaxoSmithKline Basic Information List
Table Pfizer Basic Information List
Table SP Accure Labs by Share Ltd Basic Information List
TablePfizer Basic Information List
Table Wyeth Basic Information List
Table Pfizer Basic Information List
Table Novartis Pharma Basic Information List
